Recent Updates
Recently added Catalysts

Dexlansoprazole

Phase 3

Esophagitis, Reflux | Small molecule | Other |Takeda Pharmaceutical Company Limited|Last Updated: Feb 3, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials5
Total Enrollment5,439
FDA Designations
No designations recorded
Clinical Trials (5)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00321737Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive EsophagitisPHASE3 COMPLETED 445May 1, 2006May 1, 2007Feb 3, 201298 United States, Australia +6
NCT00255151Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive EsophagitisPHASE3 COMPLETED 451Jan 1, 2006Nov 1, 2006Feb 3, 2012100 United States
NCT00255164Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive EsophagitisPHASE3 COMPLETED 451Jan 1, 2006Nov 1, 2006Feb 3, 201296 United States
NCT00251693Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPHASE3 COMPLETED 2,038Dec 1, 2005Jan 1, 2007Feb 3, 2012140 United States, Australia +13
NCT00251719Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPHASE3 COMPLETED 2,054Dec 1, 2005Jan 1, 2007Feb 3, 2012144 United States, Australia +14
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.
6 months

Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed.

Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method
6 months

Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored.

Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
8 Weeks

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
8 weeks

Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
8 Weeks

Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.

Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method
8 Weeks

Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.

Secondary Endpoints
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.
6 months
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.
6 months
Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Dexlansoprazole MR 30 mg QDEXPERIMENTAL -
Dexlansoprazole MR 60 mg QDEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Dexlansoprazole MR 90 mg QDEXPERIMENTAL -
Lansoprazole 30 mg QDACTIVE_COMPARATOR -
Interventions
NameTypeDescription
Dexlansoprazole MRDRUGDexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
PlaceboDRUGDexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
LansoprazoleDRUGLansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites98

Inclusion Criteria: * Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (...

Countries:United StatesAustraliaCanadaCzechiaEstoniaLatviaLithuaniaSlovakiaBulgariaGermanyHungaryIndiaNew ZealandPeruPolandSouth AfricaColombiaRussia
Unlock Eligibility Criteria